Inhibition of mitochondrial carnitine palmitoyltransferase-1 by a trimetazidine derivative, S-15176

Pharmacological Research

Volumn 44, Issue 2, 2001, Pages 99-104

  Hamdan, Mohamed ^a   Urien, Saik ^a   Le Louet, Herve ^a   Tillement, Jean Paul ^a   Morin, Didier ^a,b  

^a Laboratoire De Pharmacologie   (France)

^b CNRS   (France)

Author keywords

Antianginal agents; Carnitine palmitoyltransferase; Fatty acids; Malonyl CoA; Mitochondria

Indexed keywords

AMIODARONE; ANTIANGINA PECTORIS AGENT; CARNITINE PALMITOYLTRANSFERASE; N (3,5 DI TERT BUTYL 4 HYDROXY 1 THIOPHENYL) 3 PROPYL N (2,3,4 TRIMETHOXYBENZYL)PIPERAZINE; PERHEXILINE; S 15176; TRIMETAZIDINE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CELL METABOLISM; CONTROLLED STUDY; DRUG POTENCY; ENZYME INHIBITION; FATTY ACID OXIDATION; GLUCOSE OXIDATION; GLUCOSE UTILIZATION; HEART MITOCHONDRION; HEART MUSCLE METABOLISM; LIPID METABOLISM; LIVER METABOLISM; LIVER MITOCHONDRION; MALE; NONHUMAN; OXYGEN CONSUMPTION; PRIORITY JOURNAL; RAT;

EID: 0034927508     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1006/phrs.2001.0829     Document Type: Article

References (25)

1. Cloning, sequencing, and expression of a cDNA encoding rat liver carnitine palmitoyltransferase I. Direct evidence that a single polypeptide is involved in inhibitor interaction and catalytic function
2. Role of lipids and lipids metabolites in myocardial ischemia
3. Rationale and application of fatty acid oxidation inhibitors in treatment of diabetes mellitus
4. Trimetazidine increases phospholipid turnover in ventricular myocyte
5. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long chain 3-ketoacyl coenzyme A thiolase
6. Effect of trimetazidine on carnitine palmitoyltransferase-1 in the rat heart
7. S-15176 reduces the hepatic injury in rats subjected to experimental ischemia and reperfusion
8. Inhibition of carnitine palmitoyltransferase-1 in rat heart and liver by perhexiline and amiodarone
9. Isolation of liver or kidney mitochondria
10. The relationship between mitochondrial activation and toxicity of some substituted carboxylic acids
11. Protein measurement with the folin phenol reagent
12. A study of properties and abundance of the components of liver carnitine palmitoyltransferase in mitochondrial inner and outer membranes
13. Micropharm-K, a microcomputer interactive program for the analysis and simulation of pharmacokinetic processes
14. Trimetazidine: Experimental and clinical update review
15. Some biochemical aspects of the protective effect of trimetazidine on rat cardiomyocytes during hypoxie and reoxygenation
16. Effect of etomoxiryl-CoA on different carnitine acyltransferases
17. Etomoxir, a camitine palmitoyltransferase I inhibitor, protects hearts from fatty acid-induced ischemic injury independent of changes in long chain acylcarnitine
18. (+)-Hemipalmitoylcarnitinium strongly inhibits carnitine palmitoyl-transferase-I in intact mitochondria
19. Observations on the affinity for carnitine, and malonyl-CoA sensitivity, of carnitine palmitoyltransferase I in animal and human tissues. Demonstration of the presence of malonyl-CoA in non-hepatic tissues of the rat
20. Use of six chimeric proteins to determine the role of intramolecular interactions in determining the kinetic of carnitine palmitoyltransferase I isoforms
21. Cholate extracts of mitochondrial outer membranes increase inhibition by malonyl-CoA of carnitine palmitoyltransferase-I by a mechanism involving phospholipids
22. High rates of fatty acid oxidation during reperfusion of ischemic hearts are associated with a decease in malonyl-CoA levels due to an increase in 5'-AMP-activated protein kinase inhibition of acetyl-CoA carboxylase
23. Amphipathic lipid metabolites and their relation to arrhythmogenesis in the ischemic heart
24. Lysophospholipids, long chain acylcarnitines and membrane dysfunction in the ischemic heart
25. Cellular uncoupling induced by accumulation of long-chain acylcarnitine during ischemia